Structure Therapeutics Inc. American Depositary Shares (GPCR) - Total Liabilities
Based on the latest financial reports, Structure Therapeutics Inc. American Depositary Shares (GPCR) has total liabilities worth $61.03 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Structure Therapeutics Inc. American Dep to track the company's year-over-year net asset growth rate.
Structure Therapeutics Inc. American Depositary Shares - Total Liabilities Trend (2020–2025)
This chart illustrates how Structure Therapeutics Inc. American Depositary Shares's total liabilities have evolved over time, based on quarterly financial data. See GPCR FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Structure Therapeutics Inc. American Depositary Shares Competitors by Total Liabilities
The table below lists competitors of Structure Therapeutics Inc. American Depositary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
AP Memory Technology Corp
TW:6531
|
Taiwan | NT$3.56 Billion |
|
Ventia Services Group Ltd
AU:VNT
|
Australia | AU$2.34 Billion |
|
Hangzhou EZVIZ Network Co. Ltd. A
SHG:688475
|
China | CN¥2.89 Billion |
|
China Film Co Ltd
SHG:600977
|
China | CN¥8.66 Billion |
|
Stride Inc
NYSE:LRN
|
USA | $805.01 Million |
|
Golub Capital BDC Inc
NASDAQ:GBDC
|
USA | $5.00 Billion |
|
Qingdao East Steel Tower Stock Co Ltd
SHE:002545
|
China | CN¥4.54 Billion |
|
Shenzhen Yan Tian Port Holdings Co Ltd
SHE:000088
|
China | CN¥4.15 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Structure Therapeutics Inc. American Depositary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GPCR market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 26.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Structure Therapeutics Inc. American Depositary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Structure Therapeutics Inc. American Depositary Shares (2020–2025)
The table below shows the annual total liabilities of Structure Therapeutics Inc. American Depositary Shares from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $67.54 Million | +75.49% |
| 2024-12-31 | $38.49 Million | +32.48% |
| 2023-12-31 | $29.05 Million | -86.36% |
| 2022-12-31 | $212.99 Million | +21.09% |
| 2021-12-31 | $175.89 Million | +187.53% |
| 2020-12-31 | $61.17 Million | -- |
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more